Form 4: 4D Molecular Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
David Kirn, See Remarks and a Director of 4D Molecular Therapeutics, Inc., sold 69,076 shares of common stock on August 19, 2026.
Summary
- Option exercise/conversion: acquired 50,000 Common Stock at $4.14 ($207,000) on August 19, 2026; holds 894,895 after (Direct).
- Open-market sale: disposed of 43,149 Common Stock at $15.36 ($662,622) on August 19, 2026; holds 851,746 after (Direct).
- Open-market sale: disposed of 25,927 Common Stock at $16.42 ($425,651) on August 19, 2026; holds 825,819 after (Direct).
- Option exercise/conversion: disposed of 50,000 Stock Option (Right to Buy) on August 19, 2026; holds 217,500 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,088,273 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David Kirn — Director, Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-19 | Option exercise/conversion | Common Stock | 50,000 | $4 | $207.0K | 894,895 |
| 2026-08-19 | Open-market sale | Common Stock | 43,149 | $15 | $662.6K | 851,746 |
| 2026-08-19 | Open-market sale | Common Stock | 25,927 | $16 | $425.7K | 825,819 |
| 2026-08-19 | Option exercise/conversion | Stock Option (Right to Buy) | 50,000 | — | — | 217,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-19 | Option exercise/conversion (50,000 shares) |
| 2026-08-19 | Open-market sale (43,149 shares) |
| 2026-08-19 | Open-market sale (25,927 shares) |
| 2026-08-19 | Option exercise/conversion (50,000 shares) |
Keywords
insider transaction, Form 4, FDMT, 4D Molecular Therapeutics, Inc., bearish, David Kirn
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.